Life Without Waiting: Singapore’s UL Cell Launches Regenerative OS™ — Bringing Donor-Free, Gene-Free Regeneration to Hospitals

A collaborative breakthrough by leading scientific teams from Singapore and China, empowering hospitals to manufacture personalised regenerative cells without donors, genes or delays.

Singapore / Shanghai, 13 June 2025 —
When every second counts, patients who need advanced cell therapies still face a harsh reality: long searches for compatible donors, weeks of off-site manufacturing and the risks associated with gene-modified products. UL Cell Therapeutic, a biotechnology company headquartered in Singapore, is working to rewrite that script.

Today the company unveiled Regenerative OS™, a fully deployable operating system that allows hospitals to generate patient-specific regenerative cells on-site — no donors required, no gene editing involved, and no lengthy production queue. Developed jointly by top scientific teams in Singapore and China, the platform transitions cell therapy from a centralised, donor-dependent model to a true point-of-care capability.

A New Operating System for Regenerative Medicine

At the heart of Regenerative OS™ lie three integrated modules that create a seamless “sample-in, cells-out” workflow:

Together, these modules eliminate the three main bottlenecks of conventional cell therapy: donors, gene alteration and distant factories.

From Factory-Dependent to Hospital-Enabled

“Regenerative OS™ is more than a product — it’s a foundational operating system,” said Jeff Low, Founder and CEO of UL Cell Therapeutic.

“Every hospital should be able to create safe, personalised regenerative cells on its own site. No more donor searches. No genetic manipulation. Just your own cells — for your own healing.”

By embedding manufacturing capability inside hospitals, Regenerative OS™ has the potential to turn cell therapy from a scarce specialty into a scalable clinical service that any accredited medical centre can offer.

Deployment and Outlook

• RUO progress – Regenerative OS™ is already running under Research-Use-Only     conditions in several Asian hospitals. Early operational feedback and     safety monitoring have been positive.

• Data pipeline – Pre-clinical results are being compiled for peer-reviewed     publication and regulatory consultation.

• Future network – UL Cell aims to build a Global Regenerative Node Network™,     enabling hospitals worldwide to act as autonomous hubs for donor-free,     gene-free, on-demand cell regeneration.

Media Contact

Kristy Kang
Kristy.kang@acn.ventures
www.ulcell.bio

Regenerative OS™ is currently designated for Research Use Only (RUO) and is not yet cleared for therapeutic or diagnostic application in humans.